Sign up
Quantellect · Analysts · Analyst Profile
Analyst Score Rank#87 of 589

Brian Cheng

JP Morgan · Equity Research Analyst
ProvisionalRating since 2023No new ratings since Nov 2025

Analyst rating accuracy & track record

Brian Cheng is an equity research analyst at JP Morgan. Quantellect has scored 25 of their stock calls across 15 companies. Their picks beat their sector 51% of the time over the next 12 months, and their price targets were reached — of the time within a year.

Win % vs sector
51%
PT Hit % (12mo)
—
Avg sector-excess
+3.7%
Scored calls
25
Tickers
15
Tier
Provisional

Track record

Quantellect has scored 25 of Brian Cheng's stock calls across 15 companies, dating back to 2023. Their rated stocks beat their own sector 51% of the time over the next 12 months. On a typical call, a Cheng pick returned +3.7% more than its sector over the following year.

Of the scored calls, 22 were bullish (Buy) and 3 were bearish (Sell). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
PTGXProtagonist Therapeutics Inc
Buy$81.00Nov 2025+34.3%Hit
RVMDRevolution Medicines Inc
Buy$82.00Nov 2025+187.6%Hit
XNCRXencor Inc
Buy$18.00Nov 2025+129.7%Hit
ZYMEZymeworks Inc. Common Stock
Buy$23.00Oct 2025+11.7%Hit
ALLOAllogene Therapeutics Inc
Sell—Oct 2025+11.9%—
ABSIAbsci Corp
Buy—Oct 2025+211.8%—
ABSIAbsci Corp
Buy—Oct 2025+211.8%—
IMVTImmunovant Inc
Buy$33.00Sep 2025+88.4%Hit
CGONCG Oncology, Inc. Common stock
Buy$47.00Sep 2025+51.0%Hit
CRSPCrispr Therapeutics AG
Buy$70.00Sep 2025−33.0%Hit
IMVTImmunovant Inc
Buy$37.00Aug 2025+140.1%Hit
IMNMImmunome Inc
Buy$22.00Aug 2025+129.4%Hit
CGONCG Oncology, Inc. Common stock
Buy$41.00May 2025+133.6%Hit
AAPGAscentage Pharma Group International
Buy—Mar 2025+5.5%—
EDITEditas Medicine Inc
Sell—Dec 2024−52.5%—
ZYMEZymeworks Inc. Common Stock
Buy$18.00Dec 2024+80.7%Hit
XNCRXencor Inc
Buy$28.00Nov 2024−40.2%Miss
XNCRXencor Inc
Buy$27.00Jul 2024−45.9%Hit
KYTXKyverna Therapeutics, Inc. Common Stock
Buy$33.00Jul 2024−42.3%Miss
IMNMImmunome Inc
Buy$24.00Apr 2024−41.7%Miss
PGENPrecigen Inc
Sell—Mar 2024−26.1%—
KYTXKyverna Therapeutics, Inc. Common Stock
Buy$39.00Mar 2024−94.4%Miss
BCABBioatla Inc
Buy$14.00Sep 2023−24.1%Miss
BCABBioatla Inc
Buy$17.00Aug 2023−57.3%Miss
BCABBioatla Inc
Buy$19.00Apr 2023+12.4%Miss
Prev1Next
Go to

Brian Cheng: analyst track record FAQ

Is Brian Cheng a good stock analyst?

Yes, by track record. Brian Cheng ranks number 87 of 589 of the analysts Quantellect scores, with an Analyst Score of 61 out of 100. Past results do not guarantee future ones.

What is Brian Cheng's win rate?

Brian Cheng's win rate is 51%. Across 25 scored calls, their rated stocks beat their sector 51% of the time over the next 12 months. On a typical call they returned +3.7% more than the sector.

What stocks and sectors does Brian Cheng cover?

Brian Cheng covers 15 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Brian Cheng's price targets accurate?

Brian Cheng's price targets are reached within 12 months — of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Brian Cheng's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Brian Cheng rank among Wall Street analysts?

Brian Cheng ranks number 87 of 589 by Analyst Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.